Image credit: shutterstock
China-based Biocytogen Pharmaceuticals has announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Jonson & Johnson.
Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite platform and underlying intellectual property to discover, research, develop, manufacture and commercialise fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC.
RenLite is a member of Biocytogen’s fully human antibody RenMice family. RenLite mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development.
